Market capitalization | $68.89m |
Enterprise Value | $22.23m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 35.29 |
P/S ratio (TTM) P/S ratio | 109.35 |
P/B ratio (TTM) P/B ratio | 0.90 |
Revenue growth (TTM) Revenue growth | 113.07% |
Revenue (TTM) Revenue | $630.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Ovid Therapeutics Inc. forecast:
9 Analysts have issued a Ovid Therapeutics Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.63 0.63 |
110%
110%
|
|
Gross Profit | -0.22 -0.22 |
84%
84%
|
|
EBITDA | -68 -68 |
33%
33%
|
EBIT (Operating Income) EBIT | -69 -69 |
30%
30%
|
Net Profit | -33 -33 |
33%
33%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Head office | United States |
CEO | Jeremy Levin |
Employees | 40 |
Founded | 2014 |
Website | www.ovidrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.